Speqta is selling Rahalaitos to Sambla
Speqta AB (publ) (“Speqta”) has entered into an agreement with Nordic Capital owned Sambla Group AB (“Sambla”) to sell the leading loan broker in Finland, Eone Oy (“Rahalaitos”), for approximately EUR 48.4 million (EUR 45.5 million cash free basis) by divestment of all shares in the subsidiary Rahalaitos (the “Transaction”). The purchase price will be paid in cash and is divided into a payment of approximately EUR 40.4 million (EUR 37.5 million cash free basis) to be paid in the beginning of December 2021, and an additional payment of maximum EUR 8.0 million. The sale entails
Stockholm, November 8, 2021 - Intervacc AB (“Intervacc”) announces that the United States Patent and Trademark Office has granted an approval for Intervacc's patent application in the United States for a vaccine against Streptococcus suis infections. The U.S. Patent No. 11,155,585 relates to a vaccine based on recombinant fusion proteins where patent protection is effective until 2037.
The bacterium Streptococcus suis (S. suis) can cause sepsis, arthritis and meningitis in pigs. S. suis infection is one of the most common bacterial causes of fatal infection in recently weaned pigs and is
